FKD Secures Expertise for Gene Therapy Phase II Trial
By Nuala Moran
Wednesday, August 1, 2012
LONDON FKD Therapies Oy has secured the support of the leading urologic oncologists in the U.S. for the Phase II trial of Instiladrin, a gene therapy treatment for bladder cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.